Insight Molecular Diagnostics Inc - IMDX Price-to-Projected Revenue Ratio

The implementation of ESG standards and the eco-friendly disposal of biomaterials are becoming key growth drivers for Insight Molecular Diagnostics (IMDX). The projected price-to-sales valuation visualizes this trend, where the 44.70 mark reflects the latest data. Growth is supported by patents for liquid biopsy in oncology diagnostics, as well as the brand's impeccable reputation for developing high-precision genetic tests for clinics.

Insight Molecular Diagnostics Inc - IMDX Market Cap to Expected Sales Ratio (period 06/19/2025 - 11/13/2026)

Comprehensive metric breakdowns and analytics for imdxinc.com (IMDX)

- market price and analyst price targets:

Price Chart Insight Molecular Diagnostics Inc|IMDX - Broker Consensus Forecast

- issuer market value details:

Market Value IMDX|IMDX - Company Buyout Price

- book value of equity indicators:

Book Value per Share Insight Molecular Diagnostics|IMDX - Book Valuation of Business|Market Capitalization to Book Value Ratio imdxinc.com|IMDX - Company Balance Sheet Assets

- company liabilities and liquidity data:

Total Debt to Capital Insight Molecular Diagnostics|IMDX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Insight Molecular Diagnostics Inc|IMDX - Company Cumulative Indebtedness|Debt to Book Value IMDX|IMDX - Company Long-Term Loans and Borrowings|Company Short-Term Debt Insight Molecular Diagnostics|Quick Liquidity imdxinc.com

- financial results and valuation multiples details:

IMDX - Company Net Income|Expected Profit Insight Molecular Diagnostics|IMDX - Price to Earnings Ratio|Forward P/E Multiple Insight Molecular Diagnostics Inc|IMDX - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple IMDX|IMDX - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Insight Molecular Diagnostics|IMDX - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months imdxinc.com|IMDX - Earnings per share growth in current year|Earnings growth forecast for next year Insight Molecular Diagnostics

- sales volume and revenue indicators:

IMDX - Revenue and Sales Volume|Company Projected Revenue Insight Molecular Diagnostics Inc|IMDX - Market Capitalization-to-Revenue Ratio|Forward Price-to-Revenue Multiple IMDX

General company analysis:Insight Molecular (IMDX)

Product sample of Insight Molecular Diagnostics, Inc.

The forward P/S ratio compares the current market capitalization of Insight Molecular Diagnostics (IMDX) with expected revenue, allowing for an assessment of the premium for future sales growth per unit of income. Given the stability of Western jurisdictions and the humanitarian status of molecular diagnostics, the forward P/S valuation history reflects market confidence in the predictability of the company's cash flows, helping investors determine the boundary between fair value and overpayment.

Key competitors

Price-to-Projected Revenue Ratio Agilent A|DGX: Market Cap to Projected Revenue|ILMN - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Exact Sciences Inc. EXAS|RVTY: Forward P/S Multiple|BIO - Market Cap to Expected Sales Ratio|NNNN (Anbio) - Forward P/S Multiple|SHC - Projected Price to Revenue|Forward P/S Multiple QDEL|OPK (OPKO Health Corp.) - Forward Price to Sales|CareDx, Inc - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio MRVI (maravai.com)|FLGT: Forward Price-to-Revenue Multiple|Forward Price to Sales LAB (Standard BioTools Inc)|Cytek Bio (CTKB) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple OraSure Corp|Price-to-Projected Revenue Ratio Exagen Inc|Market Cap to Future Revenue Ratio mdxhealth.com MDXH|Price-to-Projected Revenue Ratio Lucid Diagnostics (LUCD)|Price-to-Projected Revenue Ratio PRE (prenetics.com)|Forward P/S Multiple TRIB (Trinity Biotech)|ProPhase Labs Corp (PRPH) - Market Cap to Future Revenue Ratio|Ainos, Inc. - Forward P/S Multiple|codiagnostics.com (CODX) - Forward Price-to-Revenue Multiple|HSCS (HeartSciences) - Forward Price-to-Revenue Multiple|Biomerica Inc. (BMRA) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Cardio Diagnostics Holdings Inc.|Price-to-Projected Revenue Ratio ONCO|Forward P/S Multiple VRAX|Forward P/S Multiple bluejaydx.com (BJDX)|Price-to-Projected Revenue Ratio Aspira Women's Health Inc. AWH|Forward Price to Sales AXDX|CNTG: Forward Price-to-Revenue Multiple|Forward Price to Sales ENZ (Enzo Biochem, Inc.)|FRES: Forward P/S Multiple|Market Cap to Projected Revenue GENE|ME (23andMe) - Forward P/S Multiple|Psychemedics Corp. (PMD) - Market Cap to Expected Sales Ratio